Author:
Lutfor Nessa,Arjan Singh,Muhammad Waqar Sharif,Joud Enabi,Mamoun Bashir
Abstract
Objective: This case study presents a young female patient diagnosed with symptomatic electrolyte disturbances, later confirmed as Gitelman syndrome (GS). It highlights the underlying pathophysiology and emphasizes the importance of its proper management. Background: GS is a rare genetic disorder affecting kidney electrolyte reabsorption, leading to symptoms like weakness, muscle cramps, fatigue, nausea, and vomiting. Diagnosis involves lab tests and genetic confirmation, with treatment comprising electrolyte supplementation and medications. Ongoing management is vital to prevent complications. Case presentation: A 23-year-old Caucasian female presented to the ED with sudden weakness in all extremities, thirst, and lightheadedness. Lab results showed hyperglycemia 166 (70-100 mg/dL), severe hypokalemia 1.1 (3.6-5.1 mmol/L), mild hypercalcemia 11 (8.9-10.4 mg/dL), and severe hypophosphatemia 0.6 (2.3-7.0 mg/dL). Incidentally, she had prior hypokalemia history from a motor accident hospitalization and managed it with KCl for a year but stopped when symptoms improved. She was treated with electrolyte replacement and discharged with oral potassium. Five days later, she returned with severe hypokalemia 1.3, mild hypercalcemia 10.7, and severe hypophosphatemia 0.6. A 24-hour urinary test showed distal convoluted tubulopathy indicative of GS. She was treated with replacement therapy and spironolactone, with instructions for ongoing supplementation and follow-up with a nephrologist. Discussion: GS is mostly caused by mutations in the SLC12A3 gene, affecting the kidneys’ sodium chloride cotransporter function, as confirmed in our patient. Conclusion: While GS has no cure, appropriate treatment with medication and dietary adjustments can enhance patients’ quality of life by maintaining electrolyte balance. Healthcare providers’ awareness is crucial for effective care and complication prevention.
Publisher
Heighten Science Publications Corporation
Reference15 articles.
1. 1. Gitelman HJ, Graham JB, Welt LG. A new familial disorder characterized by hypokalemia and hypomagnesemia. Trans Assoc Am Physicians. 1966;79:221-35. PMID: 5929460.
2. 2. Parmar MS, Muppidi V, Bashir K. Gitelman Syndrome. In StatPearls. StatPearls Publishing. 2023.
3. 3. Kondo A, Nagano C, Ishiko S, Omori T, Aoto Y, Rossanti R, Sakakibara N, Horinouchi T, Yamamura T, Nagai S, Okada E, Shima Y, Nakanishi K, Ninchoji T, Kaito H, Takeda H, Nagase H, Morisada N, Iijima K, Nozu K. Examination of the predicted prevalence of Gitelman syndrome by ethnicity based on genome databases. Sci Rep. 2021 Aug 9;11(1):16099. doi: 10.1038/s41598-021-95521-6. PMID: 34373523; PMCID: PMC8352941.
4. 4. Urwin S, Willows J, Sayer JA. The challenges of diagnosis and management of Gitelman syndrome. Clin Endocrinol (Oxf). 2020 Jan;92(1):3-10. doi: 10.1111/cen.14104. Epub 2019 Oct 6. PMID: 31578736.
5. 5. Ungaro CM, Odstrcil-Bobillo MS, Russo PM. Síndrome de Gitelman [Gitelman syndrome]. Medicina (B Aires). 2020;80(1):87-90. Spanish. PMID: 32044746.